From b7c946cc55262d893d6e7d57f027fa59d0405b0d Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Wed, 18 Mar 2026 11:15:08 +0000 Subject: [PATCH] auto-fix: strip 4 broken wiki links Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base. --- ...model makes the net cost impact inflationary through 2035.md | 2 +- ...alue-across-kidney-cardiovascular-and-metabolic-endpoints.md | 2 +- ...delays-dialysis-creating-largest-per-patient-cost-savings.md | 2 +- ...ts touch value metrics but only 14 percent bear full risk.md | 2 +- 4 files changed, 4 insertions(+), 4 deletions(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 2191aa00c..7d156e218 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -79,7 +79,7 @@ Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF ### Additional Evidence (extend) -*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16* +*Source: 2026-02-01-cms-balance-model-details-rfa-design | Added: 2026-03-16* BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plus manufacturer-funded lifestyle support represents the first major policy attempt to address the chronic-use cost structure. The Medicare GLP-1 Bridge (July 2026) provides immediate price relief while full model architecture is built, indicating urgency around cost containment. diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index 53508a0f3..614d34dac 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -50,7 +50,7 @@ FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0 ### Additional Evidence (extend) -*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16* +*Source: 2025-01-01-select-cost-effectiveness-analysis-obesity-cvd | Added: 2026-03-16* Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. Diabetes prevention is the dominant economic driver, not cardiovascular protection, suggesting targeting should prioritize metabolic risk over CV risk. diff --git a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md index 25da0b0f3..2ac521e13 100644 --- a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md +++ b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md @@ -36,7 +36,7 @@ FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major k ### Additional Evidence (confirm) -*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16* +*Source: 2025-01-01-select-cost-effectiveness-analysis-obesity-cvd | Added: 2026-03-16* SELECT trial economic model shows $2,074 per-subject lifetime savings from avoided CKD, supporting the claim that kidney protection generates substantial cost savings. However, diabetes prevention ($14,431) generates even larger savings. diff --git a/domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md b/domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md index 2ee647f95..08ecde044 100644 --- a/domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md +++ b/domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md @@ -49,7 +49,7 @@ The BALANCE Model moves payment toward genuine risk by adjusting capitated rates ### Additional Evidence (extend) -*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16* +*Source: 2026-02-01-cms-balance-model-details-rfa-design | Added: 2026-03-16* CMS BALANCE Model demonstrates policy recognition of the VBC misalignment by implementing capitation adjustment (paying plans MORE for obesity coverage) plus reinsurance (removing tail risk) rather than expecting prevention incentives to emerge from capitation alone. This is explicit structural redesign around the identified barriers.